Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure
Clinical trial NCT07095803 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07095803
- Sponsor
- Sheng Zhang
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-01
- Primary completion
- 2026-02-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.